hotspot -WSS

hotspot

author：explore 2025-10-02 22:57:33 - browse：44882

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： NIH nominee Bertagnolli will get October confirmation hearing

WSS

Trump surgeon general acknowledges mistakes during Covid

How to protect patients from sexual assault

UHS says company favors patients whose insurance pays more

Why Novartis is changing the name of its research labs

New Alzheimer's drugs heat up race for early detection blood tests

Humana sues Biden admin over Medicare Advantage audit rule

explore

hotspot

leisure time

Virginia high school admissions case could be legal follow

The 10 drugs up first for Medicare price negotiation

ChatGPT in medicine: STAT answers readers' burning questions

How to protect patients from sexual assault

Jerome Adams on the need for new antivirals for Covid

Rise in cancer among younger people worries and puzzles doctors

BioMarin wins approval for gene therapy to treat hemophilia A

'Investigate these claims': UFO transparency at center of House hearing

23andMe had bad news about my health. I wish a person had delivered it

Will the FTC rein in IQVIA's health data empire?

knowledge

Why patients can’t get everything they want on drug pricing

Amazon on where the company's health care bets are headed next

ALS advocates say criticism of new drugs misses bigger picture

How to protect patients from sexual assault

The haunting brain science of long Covid

Advances in CAR

focus

hotspot

hotspot

explore